Insider Selling: Phreesia (NYSE:PHR) CFO Sells $43,114.54 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,829 shares of Phreesia stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total transaction of $43,114.54. Following the completion of the transaction, the chief financial officer directly owned 146,740 shares of the company’s stock, valued at approximately $1,652,292.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Friday, January 16th, Balaji Gandhi sold 4,687 shares of Phreesia stock. The stock was sold at an average price of $16.36, for a total transaction of $76,679.32.
• On Thursday, January 15th, Balaji Gandhi sold 975 shares of Phreesia stock. The stock was sold at an average price of $16.38, for a total transaction of $15,970.50.
• On Thursday, January 8th, Balaji Gandhi sold 8,009 shares of Phreesia stock. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09.

Phreesia Trading Up 4.1%

NYSE PHR opened at $11.43 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia, Inc. has a one year low of $10.75 and a one year high of $32.76. The company has a 50-day simple moving average of $12.51 and a 200-day simple moving average of $17.68. The firm has a market capitalization of $689.36 million, a PE ratio of -114.33 and a beta of 0.67.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The business had revenue of $127.07 million for the quarter, compared to analyst estimates of $126.75 million. During the same quarter last year, the company earned ($0.11) EPS. Phreesia’s revenue was up 15.9% compared to the same quarter last year. On average, equities analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Federated Hermes Inc. bought a new position in Phreesia in the 3rd quarter worth approximately $32,000. Van ECK Associates Corp raised its stake in Phreesia by 78.7% during the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock valued at $42,000 after acquiring an additional 1,102 shares in the last quarter. Asset Management One Co. Ltd. bought a new stake in Phreesia during the 3rd quarter valued at $45,000. Rockefeller Capital Management L.P. boosted its position in Phreesia by 354.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock worth $47,000 after acquiring an additional 2,149 shares during the period. Finally, KBC Group NV boosted its position in Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock worth $58,000 after acquiring an additional 1,568 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Barclays cut their price target on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th. Canaccord Genuity Group dropped their target price on Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, December 9th. Royal Bank Of Canada began coverage on Phreesia in a research note on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 target price on the stock. JPMorgan Chase & Co. reduced their price target on shares of Phreesia from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 20th. Finally, Mizuho lowered their price target on shares of Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, March 24th. Seventeen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Phreesia presently has a consensus rating of “Moderate Buy” and an average price target of $28.65.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Phreesia reported strong cash and profitability milestones — the company said it achieved positive GAAP net income, crossed $100M of Adjusted EBITDA and generated >$50M of free cash flow for fiscal 2026, which supports balance‑sheet strength and reduces execution risk. Business Wire: Phreesia Announces Fourth Quarter Fiscal 2026 Results
• Neutral Sentiment: Earnings call transcript and supplemental materials provide management detail on outlook and drivers — read for specifics on where guidance was trimmed and how management plans to prioritize growth vs. margins. Earnings Call Transcript
• Neutral Sentiment: Wall Street entered the quarter with reduced expectations (analyst EPS forecasts down ahead of the print); analysts are actively revising models after the report, so near‑term target/ratings changes are likely. Benzinga: Analysts Revamp Expectations
• Negative Sentiment: EPS missed consensus (reported $0.02 vs. ~$0.07 expected) and management cut revenue guidance, prompting a sharp selloff as investors reprice growth and profitability expectations. Investing.com: Shares tumble 22% on earnings miss, slashed guidance
• Negative Sentiment: MarketWatch reports the stock touched all‑time lows following the guidance cut, reflecting investor concern about near‑term growth trajectory and valuation at current levels. MarketWatch: Shares Touch All‑time Lows
• Negative Sentiment: Insider selling: CFO Balaji Gandhi sold shares recently (SEC Form 4), which may be viewed negatively by some investors though he retains a large stake. SEC Form 4: CFO sale

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.